Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophosphamide followed by docetaxel in primary breast cancer.

被引：0
|
作者：
Cramer, EM [1 ]
Moers, C [1 ]
Zarghooni, V [1 ]
Mallmann, P [1 ]
Warm, M [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：82S / 82S
页数：1
相关论文
共 50 条
  • [31] Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
    Razis, E
    Dimopoulus, AM
    Bafaloukos, D
    Papadimitriou, C
    Kalogera-Fountzila, A
    Kalofonos, H
    Briassoulis, E
    Samantas, E
    Keramopoulos, A
    Pavlidis, N
    Kosmidis, P
    Fountzilas, G
    CANCER INVESTIGATION, 2001, 19 (02) : 137 - 144
  • [32] Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel
    Gu, Xi
    Jia, Shi
    Wei, Wei
    Zhang, Wen-Hai
    TUMOR BIOLOGY, 2015, 36 (07) : 5529 - 5535
  • [33] Dose-dense neoadjuvant treatment with biweekly docetaxel (T) plus epirubicin (E) for locally advanced breast cancer (LABC).: An ONCOPAZ Cooperative Group Study.
    Borrega, P
    Lorenzo, A
    Madroñal, C
    Sanz, JJ
    Ruiz, M
    Centelles, M
    Casas, A
    de La Puente, CG
    Perez, V
    González-Barón, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 60S - 60S
  • [34] Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first line chemotherapy, in advanced breast cancer.
    Fountzilas, G
    Papadimitriou, C
    Bafaloukos, D
    Skarlos, D
    Kalofonos, HP
    Aravantinos, G
    Papakostas, P
    Kosmidis, P
    Pavlidis, N
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2000, 11 : 26 - 26
  • [35] Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer.
    Burdette-Radoux, S
    Wood, ME
    Olin, JJ
    Broom, R
    Crocker, A
    Ashikaga, T
    Muss, HB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 81S - 81S
  • [36] Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC)
    De la Cruz, S.
    Aramendia, J. M.
    Espinos, J.
    Fernandez-Hidalgo, O.
    Santisteban, M.
    Arbea, L.
    Aristu, J.
    Garran, C.
    Martinez-Monge, R.
    Martinez-Regueira, F.
    Nieto, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Dose-dense adjuvant chemotherapy for primary breast cancer
    Monica Fornier
    Larry Norton
    Breast Cancer Research, 7
  • [38] Dose-dense adjuvant chemotherapy for primary breast cancer
    Fornier, M
    Norton, L
    BREAST CANCER RESEARCH, 2005, 7 (02) : 64 - 69
  • [39] A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer
    Zhu, T.
    Liu, C. L.
    Zhang, Y. F.
    Liu, Y. H.
    Xu, F. P.
    Zu, J.
    Zhang, G. C.
    Li, X. R.
    Liao, N.
    Wang, K.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (01) : 117 - 124
  • [40] Neoadjuvant chemotherapy with a dose-dense sequential combination of epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer. Correlation between pathologic complete response (pCR) and biologic markers
    Sanchez, A.
    Duenas-Garcia, R.
    Jaen-Morago, A.
    Chacon, I.
    Garcia-Tapiador, A.
    Martinez-Ortega, E.
    de la Torre-Cabrera, C.
    Duenas, B.
    Ribelles, N.
    Sanchez-Rovira, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345